A groundbreaking Phase I trial has revealed promising results for a novel Dual-Target CAR-T cell therapy in slowing the progression of aggressive glioblastoma tumors. This innovative approach targets multiple antigens on cancer cells, enhancing the effectiveness of the treatment. The findings offer hope for improved outcomes in patients with this challenging brain cancer. Stay informed on the latest advancements in cell therapy for autoimmune diseases and other cutting-edge biotech trends by tuning into Touching Base, a dynamic podcast series featuring insightful discussions with industry experts and thought leaders.
Read more about this — here
